URGENT PANDEMIC INFORMATION

In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List


DDR, ATR and PARP Inhibitors Summit 2022


Date
Jan 25, 2022 - 09:00 AM - Jan 27, 05:00 PM
Organizer
Hanson Wade
Venue
Hyatt Regency Boston
Location
1 Avenue de Lafayette,

Boston,
MA,
US,
ZIP: 02111
Phone: +1 617 455 4188

Ticket Price: USD 2599.00 - USD 4597.00


The 5th Annual DDR, ATR & PARP Inhibitors Summit is coming at a timely inflection point within this field. With Wee1 & ATR approvals on the horizon and countless novel targets currently undergoing exciting pre-clinical validation, this unique & highly anticipated meeting unites the world experts in DDR inhibition to propel this space through the barriers it faces to clinical breakthrough.

Hosted in the biopharma hub of Boston, MA, this industry-led forum once again evolves to reflect progress in the DDR therapies field with focused content on:

PARP Inhibition: Next-Gen PARPi’s, PARP Resistance & the Future of PARP Inhibitors
Developing Clinically Successful Wee1 & ATR Inhibitors for Cancer Therapy
Developing Predictive Pre-Clinical Models in DDR to Achieve Human-Specific Translation
Novel Methodologies & Imaging Technologies to Revolutionize Pathway Understanding, Compound Optimization & Clinical Translation
Establishing a Pre-Clinically Validated Novel Target: Polθ
Identifying Reliable DDR/HR Tumor Biomarkers
Exploring the Emerging Targets in the DDR Pathway: Strategy, Execution, Development and Promise
Managing Toxicity - Dose, Delivery, Scheduling, Patient Selection, & Stratification - Managing the Therapeutic Window & Treatment Regimes
Next Steps in Combination Approaches - to Heighten Drug Effect & Overcome Resistance - What is the Future of the Field?

Prices:
Conference + 2 Workshops - Drug Developer USD 3797.00
Conference + 1 Workshop - Drug Developer USD 3398.00
Conference Only - Drug Developer USD 2999.00
Conference + 2 Workshops - Academic & Non-for-profit USD 3197.00
Conference + 1 Workshop - Academic & Non-for-profit USD 2898.00
Conference Only - Academic & Non-for-profit USD 2599.00
Conference + 2 Workshops - Product & Solution provider Pricing USD 4597.00
Conference + 1 Workshops - Product & Solution provider Pricing USD 4098.00
Conference Only - Product & Solution provider Pricing USD 3599.00

Tickets    https://go.evvnt.com/910571-1?pid=1052
Brochure https://go.evvnt.com/910571-3?pid=1052

Category: Conferences | Science, Health & Medicine | Pharmaceuticals | Drug Development


Speaker Details


Andrew Wylie Senior Vice President & Head of Oncology KSQ Therapeutics, Nathalie Agar Director of Surgical Molecular Imaging, Laboratory & Department of Neurosurgery Brigham & Women’s Hospital Department of Cancer Biology Dana-Farber Cancer Institute, Timothy Yap Associate Professor, Investigational Cancer Therapeutics MD Anderson Cancer Center, Geoffrey Shapiro Professor, Medicine, Harvard Medical School, Director of Early Drug Development Center Dana-Farber Cancer Institute, Caroline Ben Chief Scientific Officer & Co- Founder LoQus23 Therapeutics, Ioannis Gounaris Senior Medical Director Cluster Lead DNA Damage Response (DDR) Inhibitors, Global Clinical Development Oncology Group II Merck KGaA, Frank Zenke Global Head DNA Damage Response Research Merck KGaA, John Pascal Professor of Biochemistry & Molecular Medicine University of Montreal, Oren Gilad Chief Executive Officer Atrin Pharmaceuticals, Debanu Das Chief Executive Officer XPose Therapeutics, Zineb Mounir Director, Biology & Translational Science IDEAYA Biosciences, Sui Xiong Cai Executive Vice President & Chief Technology Officer IMPACT Therapeutics, Mark O’Connor Chief Scientist & Senior Principal Scientist AstraZeneca, Ranjit Bindra Professor, Departments of Therapeutic Radiology & Pathology Yale School of Medicine, Peter Huang Senior Vice President Discovery Zentalis Pharmaceuticals, Elisabetta Leo Principal Scientist - Associate Director AstraZeneca, Kent Mouw Assistant Professor of Radiation Oncology Dana-Farber Cancer Institute, Nicola Curtin Experimental Therapeutics Professor Newcastle University, Helen Robinson Vice President of Biology Artios Pharma, Alan D’Andrea Director: Center for DNA Damage and Repair, Director Susan F. Smith Center for Women’s Cancers (SFSCWC) Professor Harvard Medical School Dana-Farber Cancer Institute, Kirk Tanner Chief Scientific Officer National Brain Tumor Society, Tatjana Stankovic Institute of Cancer and Genomic Sciences University of Birmingham, Katie Pawelczak VP of Research NERx Biosciences, Sotirios Sotiriou Head of Biology & Co-Founder FoRx Therapeutics, John Pollard Vice President & Global Head of Translational Medicine & Oncology Bay, Eytan Ruppin Chief - Cancer Data Science Lab National Cancer Institute, Wael Jdey Lead Scientist Onxeo, Daniel Speidel Managing Director & Co-Founder Breakpoint Therapeutics, Graeme Smith Chief Scientific Officer Artios Pharmaceuticals, Michael Zinda Chief Scientific Officer, Executive Vice President, Head of Research & Development Repare Therapeutics, Arne Nedergaard Kousholt Postdoctoral Researcher Jos Jonkers Group, Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Asli Muvaffak Associate Director - Scientific, Oncology, Synthetic Lethality & Research Unit GSK, Laure Escoubet Vice President, Discovery Biology Zentalis Pharmaceuticals, Asima Mukhopadhyay Gynaecological Oncologist & Clinician Scientist, Chittaranjan National Cancer Institute India & Newcastle University, Jennifer Molina Principal Scientist Ribon Therapeutics

Event Categories
Keywords: oncology




Comments








Events Calendar

SunMonTueWedThuFriSat
26 27 28 29 30 31 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31 1 2 3 4 5

Newsletters

VIP Life Time Subscription to our Newsletters!
$399.99
$299.99